Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HF1K16 plus bevacizumab for recurrent or progressive glioma
CTR20262099Phase 2Active
- Sponsor
- Gaotian Biotech
- Start
- May 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules, Liposomes → Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
A Phase 2 trial of HF1K16, bevacizumab, tretinoin in glioma, sponsored by Gaotian Biotech. Started May 2026; status: active.
02
Drugs
HF1K16bevacizumabtretinoin
03
Conditions
glioma
Beyond the preview
Go deeper on CTR20262099.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20262099.